![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
DURABILITY OF SARS-COV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE
|
|
|
CROI 2022 Feb 11-16
Stefania Cicalini1, Alessandra Vergori1, Alessandro Cozzi-Lepri2, Silvia Meschi3, Veronica Bordoni4, Simone Lanini1, Daniele Lapa3, Davide Mariotti4, Lidya De Pascale1, Veronica D'Aquila1, Concetta Castilletti3, Chiara Agrati4, Enrico Girardi5, Francesco Vaia6, Andrea Antinori1.
1 HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy; 2Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK; 3Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy; 4Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy; 5Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy; 6Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy.
![0218221](../images/021822/021822-9/0218221.gif)
![0218222](../images/021822/021822-9/0218222.gif)
![0218223](../images/021822/021822-9/0218223.gif)
![0218224](../images/021822/021822-9/0218224.gif)
![0218225](../images/021822/021822-9/0218225.gif)
![0218226](../images/021822/021822-9/0218226.gif)
![0218227](../images/021822/021822-9/0218227.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|